Literature DB >> 16979386

Role of colonic fermentation in the perception of colonic distention in irritable bowel syndrome and functional bloating.

Michele Di Stefano1, Emanuela Miceli, Antonio Missanelli, Samanta Mazzocchi, Paola Tana, Gino Roberto Corazza.   

Abstract

BACKGROUND & AIMS: Bloating represents a frequent gastrointestinal symptom, but the pathophysiologic mechanism responsible for its onset is still largely unknown. Patients very frequently attribute the sensation of bloating to the presence of excessive bowel gas, but not all patients with gas-related symptoms exhibit increased intestinal production of gas. It is therefore possible that other still unrecognized mechanisms might contribute to its pathophysiology. Our aim was to evaluate whether a subgroup of patients affected by functional abdominal bloating presents hypersensitivity to colonic fermentation.
METHODS: Sixty patients affected by functional gastrointestinal disorders (11 functional bloating, 36 constipation-predominant, and 13 diarrhea-predominant irritable bowel syndrome) and moderate to severe bloating took part in the study. Twenty sex- and age-matched healthy volunteers were enrolled as a control group. All the subjects underwent a preliminary evaluation of breath hydrogen excretion after oral lactulose. Then, on a separate day, an evaluation of sensitivity thresholds at rectal level was performed with a barostat before and after the induction of colonic fermentation with oral lactulose. A control test with electrolyte solution was also performed.
RESULTS: Both breath hydrogen excretion and mouth-to-cecum transit time did not differ between the 4 groups studied. Neither electrolyte solution nor lactulose modified sensitivity thresholds in healthy volunteers. In low hydrogen producers, basal perception and discomfort thresholds were similar to high hydrogen producers, but after lactulose both perception and discomfort thresholds were significantly reduced only in low hydrogen producers.
CONCLUSIONS: A subgroup of patients with functional gastrointestinal disorders and moderate to severe bloating might have hypersensitivity to products of colonic fermentation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16979386     DOI: 10.1016/j.cgh.2006.07.004

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  6 in total

1.  The treatment of irritable bowel syndrome.

Authors:  Brian E Lacy; Kirsten Weiser; Ryan De Lee
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

2.  Prevalence and risk factors for abdominal bloating and visible distention: a population-based study.

Authors:  X Jiang; G R Locke; R S Choung; A R Zinsmeister; C D Schleck; N J Talley
Journal:  Gut       Date:  2008-06       Impact factor: 23.059

3.  Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome.

Authors:  Michele Di Stefano; Paola Tana; Caterina Mengoli; Emanuela Miceli; Elisabetta Pagani; Gino Roberto Corazza
Journal:  Intern Emerg Med       Date:  2010-12-16       Impact factor: 3.397

4.  Breath Methane Excretion Is not An Accurate Marker of Colonic Methane Production in Irritable Bowel Syndrome.

Authors:  Michele Di Stefano; Caterina Mengoli; Manuela Bergonzi; Catherine Klersy; Elisabetta Pagani; Emanuela Miceli; Gino Roberto Corazza
Journal:  Am J Gastroenterol       Date:  2015-03-24       Impact factor: 10.864

Review 5.  Prevention and Treatment of Flatulence From a Traditional Persian Medicine Perspective.

Authors:  Bagher Larijani; Mohammad Medhi Esfahani; Maryam Moghimi; Mohammad Reza Shams Ardakani; Mansoor Keshavarz; Gholamreza Kordafshari; Esmaiel Nazem; Shirin Hasani Ranjbar; Hoorieh Mohammadi Kenari; Arman Zargaran
Journal:  Iran Red Crescent Med J       Date:  2016-01-31       Impact factor: 0.611

6.  Fructose and lactose intolerance and malabsorption testing: the relationship with symptoms in functional gastrointestinal disorders.

Authors:  C H Wilder-Smith; A Materna; C Wermelinger; J Schuler
Journal:  Aliment Pharmacol Ther       Date:  2013-04-09       Impact factor: 8.171

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.